BridgeBio Oncology Therapeutics Inc. (BBOT), a clinical-stage biopharmaceutical company, on Wednesday presented promising preclinical data on BBO-11818, a drug developed for the treatment of KRAS-mutant cancers, at the 2026 annual meeting of the American Association for Cancer Research (AACR).
BBO-11818 is a selective, orally bioavailable, non-covalent inhibitor that targets mutant KRAS in both the ON (active GTP-bound) and OFF (non-active GDP-bound) states.
In preclinical testing, BBO-11818 showed inhibition of ERK phosphorylation and proliferation in KRAS-dependent cell lines in vitro. The drug was effective when combined in vivo with BBO-10203 and Cetuximab in KRAS-mutant CDX and PDX models. Additionally, BBO-11818 in combination with anti-PD-1 treatment showed strong tumor regression and the induction of an adaptive immune response.
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial.
BBOT has traded between $8.08 and $14.87 over the past year. The stock closed Wednesday's trading at $8.87, down 6.24%. In premarket trading, the stock is trading at $8.57, down 3.38%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.